First look: how a drug acts in dialysis patients
NCT ID NCT06468826
Summary
This small, early study aimed to understand how a single dose of the drug avacopan is processed by the body in two groups: people with healthy kidneys and people with end-stage kidney disease who need dialysis. The main goal was to measure the drug levels in the blood and see how much is removed during dialysis, while also checking for safety. It involved 13 participants and was not designed to treat their kidney disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE (ESRD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Floridian Clinical Research, LLC
Miami Lakes, Florida, 33016, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809-3017, United States
Conditions
Explore the condition pages connected to this study.